Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MDR

- PMLiVE

Quintiles wins New Models of Care award at PMEA

Rewarded for its rheumatology project for Pfizer

- PMLiVE

Xalkori set for rapid review in new lung cancer indication

Pfizer could produce first FDA-approved biomarker-driven therapy for ROS1-positive NSCLC

- PMLiVE

Pfizer signs $1bn cancer antibody deal with BioAtla

Aims to overcome one of the limitations of antibody-drug conjugate drugs

- PMLiVE

UK site a casualty as Pfizer reduces pain R&D

Will shut down Granta Park facility in Cambridge with loss of 120 jobs

- PMLiVE

Pfizer’s Xalkori approved for wider use in Europe

Labelupdate gives the lung cancer therapy a new first-line indication

Roche - Basel

Roche drops superbug partnership with Polyphor

But adds inflammation research agreement with Proximagen

- PMLiVE

Pfizer signs high-level deal with GPCR specialist Heptares

Wide-rangingdeal will involve up to 10 drug targets

Michael Parini moves from Pfizer to Vertex

Will be the USbiotech's chief legal officer

- PMLiVE

Pfizer and Allergan merger faces opposition over tax

Companiesagree deal to boost Pfizer's standing as world's largest pharma company

- PMLiVE

Cellectis gets big pharma partners for CAR-T therapy

Pfizer, Servier and Cellectis in three-way deal to develop CAR-T immunotherapy

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links